Gene targets for T-cell-based immunotherapy
AssigneeThe Regents of the University of California
InventorsAlexander Marson, Eric Shifrut, Julia Carnevale, Alan Ashworth
Life of this patent
Estimating the term…
Abstract
Provided herein are genetically modified T cells that exhibit increased proliferation compared to wild-type T cells when stimulated, methods of generating such T cells, and methods of using the T cells for the treatment of a disease such as cancer.
Claims10
A genetically modified hematopoietic cell that comprises a genetic modification that inhibits expression or activity of a polypeptide product encoded by a RAS p21 protein activator 2 (RASA2) gene, wherein expression or activity of the polypeptide product is inhibited by at least 60% compared to a control wild-type hematopoietic cell;
- wherein the genetically modified hematopoietic cell is a T-cell and inhibition of expression increases proliferation-of the cell induced by T-cell receptor signaling.
Dependencies are inferred from the claim text.